PF-Atlas › Clinical Trials › NCT03650075
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
MG-S-2525 · Phase 1
Registry ID
NCT03650075
Phase
Phase 1
Status
Completed
Drug / intervention
MG-S-2525
Sponsor
Metagone Biotech Inc.
Start
2019-02-25
Enrollment
81
Locations
1
About this trial
This is a Phase I stage to investigate the safety and tolerability of MG-S-2525 in healthy volunteers. The proposed trial consists of 3 study parts to be conducted at Tri-Service General Hospital and includes Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and Food Effect parts. This study will enroll up to 16 evaluable subjects in the SAD part, 36 evaluable subjects in the MAD part and enroll up to 20 evaluable subjects for the Food Effect part.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03650075 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.